305 related articles for article (PubMed ID: 19616461)
1. Docking and molecular dynamics studies toward the binding of new natural phenolic marine inhibitors and aldose reductase.
Wang Z; Ling B; Zhang R; Suo Y; Liu Y; Yu Z; Liu C
J Mol Graph Model; 2009 Sep; 28(2):162-9. PubMed ID: 19616461
[TBL] [Abstract][Full Text] [Related]
2. Phenolic marine natural products as aldose reductase inhibitors.
Manzanaro S; Salva J; de la Fuente JA
J Nat Prod; 2006 Oct; 69(10):1485-7. PubMed ID: 17067167
[TBL] [Abstract][Full Text] [Related]
3. Docking and molecular dynamics study on the inhibitory activity of coumarins on aldose reductase.
Wang Z; Ling B; Zhang R; Liu Y
J Phys Chem B; 2008 Aug; 112(32):10033-40. PubMed ID: 18637681
[TBL] [Abstract][Full Text] [Related]
4. Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase.
Lee YS; Chen Z; Kador PF
Bioorg Med Chem; 1998 Oct; 6(10):1811-9. PubMed ID: 9839011
[TBL] [Abstract][Full Text] [Related]
5. Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme.
El-Kabbani O; Ramsland P; Darmanin C; Chung RP; Podjarny A
Proteins; 2003 Feb; 50(2):230-8. PubMed ID: 12486717
[TBL] [Abstract][Full Text] [Related]
6. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors.
El-Kabbani O; Darmanin C; Schneider TR; Hazemann I; Ruiz F; Oka M; Joachimiak A; Schulze-Briese C; Tomizaki T; Mitschler A; Podjarny A
Proteins; 2004 Jun; 55(4):805-13. PubMed ID: 15146479
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs).
Reddy TN; Ravinder M; Bagul P; Ravikanti K; Bagul C; Nanubolu JB; Srinivas K; Banerjee SK; Rao VJ
Eur J Med Chem; 2014 Jan; 71():53-66. PubMed ID: 24275248
[TBL] [Abstract][Full Text] [Related]
8. Kinetics and molecular docking studies of kaempferol and its prenylated derivatives as aldose reductase inhibitors.
Jung HA; Moon HE; Oh SH; Kim BW; Sohn HS; Choi JS
Chem Biol Interact; 2012 May; 197(2-3):110-8. PubMed ID: 22543015
[TBL] [Abstract][Full Text] [Related]
9. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
[TBL] [Abstract][Full Text] [Related]
10. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations.
Sotriffer CA; Krämer O; Klebe G
Proteins; 2004 Jul; 56(1):52-66. PubMed ID: 15162486
[TBL] [Abstract][Full Text] [Related]
11. High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor Fidarestat: stereospecific interaction between the enzyme and a cyclic imide type inhibitor.
El-Kabbani O; Darmanin C; Oka M; Schulze-Briese C; Tomizaki T; Hazemann I; Mitschler A; Podjarny A
J Med Chem; 2004 Aug; 47(18):4530-7. PubMed ID: 15317464
[TBL] [Abstract][Full Text] [Related]
12. Electrostatic fields near the active site of human aldose reductase: 1. New inhibitors and vibrational stark effect measurements.
Webb LJ; Boxer SG
Biochemistry; 2008 Feb; 47(6):1588-98. PubMed ID: 18205401
[TBL] [Abstract][Full Text] [Related]
13. The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant.
Harrison DH; Bohren KM; Petsko GA; Ringe D; Gabbay KH
Biochemistry; 1997 Dec; 36(51):16134-40. PubMed ID: 9405046
[TBL] [Abstract][Full Text] [Related]
14. Subatomic and atomic crystallographic studies of aldose reductase: implications for inhibitor binding.
Podjarny A; Cachau RE; Schneider T; Van Zandt M; Joachimiak A
Cell Mol Life Sci; 2004 Apr; 61(7-8):763-73. PubMed ID: 15095001
[TBL] [Abstract][Full Text] [Related]
15. Charge density and electrostatic interactions of fidarestat, an inhibitor of human aldose reductase.
Fournier B; Bendeif el-E; Guillot B; Podjarny A; Lecomte C; Jelsch C
J Am Chem Soc; 2009 Aug; 131(31):10929-41. PubMed ID: 19594152
[TBL] [Abstract][Full Text] [Related]
16. High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group.
Steuber H; Zentgraf M; Podjarny A; Heine A; Klebe G
J Mol Biol; 2006 Feb; 356(1):45-56. PubMed ID: 16337231
[TBL] [Abstract][Full Text] [Related]
17. 6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2.
Kato A; Kobayashi K; Narukawa K; Minoshima Y; Adachi I; Hirono S; Nash RJ
Bioorg Med Chem Lett; 2010 Oct; 20(19):5630-3. PubMed ID: 20805028
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and evaluation of rhodanine derivatives as aldose reductase inhibitors.
Agrawal YP; Agrawal MY; Gupta AK
Chem Biol Drug Des; 2015 Feb; 85(2):172-80. PubMed ID: 24903533
[TBL] [Abstract][Full Text] [Related]
19. (4-Oxo-2-thioxothiazolidin-3-yl)acetic acids as potent and selective aldose reductase inhibitors.
Kucerova-Chlupacova M; Halakova D; Majekova M; Treml J; Stefek M; Soltesova Prnova M
Chem Biol Interact; 2020 Dec; 332():109286. PubMed ID: 33038328
[TBL] [Abstract][Full Text] [Related]
20. Structural and thermodynamic study on aldose reductase: nitro-substituted inhibitors with strong enthalpic binding contribution.
Steuber H; Heine A; Klebe G
J Mol Biol; 2007 May; 368(3):618-38. PubMed ID: 17368668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
